Ningetinib tosylate clinical trials
A product of Ningetinib; its studies count on that page too.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses ningetinib tosylate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2014 (1)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Ningetinib
- One of Protein Kinase Inhibitors source
- One of Tyrosine kinase inhibitors (TKIs) source
Studies
Open first, then newest update. How each study uses ningetinib tosylate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping MutationsWithdrawnPhase 2Sunshine Lake Pharma Co., Ltd.NCT04992858Written as CT053PTSA
- Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M NegativeCompletedPhase 1/2Sunshine Lake Pharma Co., Ltd.NCT03758287Written as CT053PTSA
- A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)TerminatedPhase 1Sunshine Lake Pharma Co., Ltd.NCT03125876Written as CT053PTSA
- A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCCTerminatedPhase 1/2Sunshine Lake Pharma Co., Ltd.NCT03876925Written as CT053PTSA
- First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid TumorsCompletedPhase 1Sunshine Lake Pharma Co., Ltd.NCT04577703Written as CT053PTSA
Codes
What other systems call ningetinib tosylate · ClinicalTrials.gg INT017770
- UNII (FDA) R7I5725FESNINGETINIB TOSYLATEOne source FDA
- NCI Thesaurus C148529Ningetinib TosylateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | R7I5725FES | NINGETINIB TOSYLATE | One source FDA |
| NCI Thesaurus | C148529 | Ningetinib Tosylate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.